Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONVINCE low-dose colchicine for secondary prevention after non-cardioembolic ischemic stroke or high-risk TIA
MOH_2020-04-13_007183Phase 3Not yet recruiting
- Sponsor
- פרופ דוד טנה
- Start
- Jun 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ischemic stroke and transient ischaemic attack (TIA) comparing Colchicine plus standard care with Placebo or control plus standard care (2 arms). Primary endpoint: Recurrent nonfatal ischemic stroke or transient ischemic attack. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on MOH_2020-04-13_007183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-04-13_007183.